In January 2018, the Prostate Cancer Foundation recognized the developments of PSMA radionuclide therapy as one of the top 5 research stories of 2017, highlighting the recent work from Weill Cornell Medicine’s Department of Urology as a driving force behind this effort.
Researchers at Weill Cornell Medicine, including Drs. Neil Bander, Scott Tagawa, and Shankar Vallabhajosula, are currently conducting clinical research on metastatic prostate cancer, looking at the oncologic impact of radiopharmaceuticals that target PSMA on the surface of prostate cancer cells.
This research project was greatly supported by the receipt of the Prostate Cancer Foundation’s 2017 PCF Challenge award in October 2017, granting $1 Million to further clinical trials in this area.
To learn more about PSMA Targeted Therapeutic Agent clinical research at Weill Cornell Medicine, please visit: First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer
To read the full feature and learn about PCF’s other top stories in prostate cancer research, please visit: Prostate Cancer Foundation – Top 5 Prostate Cancer Research Stories in 2017
